• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Prevention and therapy of arteriosclerosis (author's transl)].

作者信息

Hauss W H

出版信息

Aktuelle Gerontol. 1978 Dec;8(12):653-60.

PMID:33560
Abstract

Arteriosclerosis is caused by many factors. These pathogenic factors especially over-nutrition, nicotinabusus, deficiency of muscular exercise, muscular overstrain, emotional stress and concomitant basic diseases, especially arterial hypertension, diabetes mellitus and dyslipidemia are the most important points for preventive and therapeutical action. When possible the risk factors has to be eliminated, arterial hypertension, diabetes mellitus and dyslipidemia have to be treated orderly. In the pathogenesis of arteriosclerosis and atherosclerosis are known disturbances of the lipid metabolism, the blood coagulation and the metabolism of the arterial wall cells most important. Application of anticoagulants and lipid lowering medicaments did not come up to our expectations. Experiences with animal models and a double blind study (secondary prevention of myocardial infarction) have given good reason for recommending antirheumatic or as we like to say, mesenchyme suppressive drugs.

摘要

相似文献

1
[Prevention and therapy of arteriosclerosis (author's transl)].
Aktuelle Gerontol. 1978 Dec;8(12):653-60.
2
The hidden effects of antihypertensive and lipid-lowering agents on the prevention and regression of atherogenesis: new management strategies.
R I Med. 1995 Mar;78(3):78-81.
3
Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes.糖尿病患者动脉粥样硬化的预防:重点关注糖尿病异常脂蛋白代谢的治疗。
Clin Ther. 1993 Sep-Oct;15(5):766-78; discussion 765.
4
Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.辛伐他汀对2型糖尿病患者的降脂作用。
Indian Heart J. 2001 Mar-Apr;53(2):172-6.
5
[Dyslipidemia, lipid lowering drugs and thrombosis].[血脂异常、降脂药物与血栓形成]
Arch Mal Coeur Vaiss. 1995 Nov;88(11):1641-5.
6
[Phosphatidylcholine in the control of arteriosclerosis].
Clin Ter. 1984 Oct 15;111(1):27-44.
7
[The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis].[动脉粥样硬化中脂质代谢紊乱的药理学纠正的可能手段]
Eksp Klin Farmakol. 1997 Mar-Apr;60(2):78-85.
8
[Biochemical and experimental aspects of the lipid-lowering drugs pharmacology (author's transl)].
Sem Hop. 1979;55(41-42):1947-55.
9
Update on risk factors for atherosclerosis: the role of inflammation and apolipoprotein E.动脉粥样硬化危险因素的最新进展:炎症和载脂蛋白E的作用
Medsurg Nurs. 2005 Feb;14(1):43-50.
10
Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data.糖尿病血脂异常:在缺乏临床试验和成本效益数据的情况下进行积极干预的理由。
Can J Cardiol. 1995 May;11 Suppl C:24C-28C.